{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:38:48Z","timestamp":1783435128359,"version":"3.54.6"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Access Publication Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated. Detailed information about the clinical characteristics of this form of headache has not yet been described. The aim of the study is to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA COVID-19 vaccine for the first time. In a multicentre observational cohort study, data on the clinical features and corresponding variables were recorded using a standardized online questionnaire. The questionnaire was circulated to 12\u2009000 residential care homes of the elderly as well as tertiary university hospitals in Germany and the United Arab Emirates. The primary outcomes of this study are the clinical features of headache after vaccination. Comorbidities, treatment with medication and sociodemographic variables are also analysed. A total of 2349 participants reported headaches after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Headaches occur an average of 18.0\u2009\u00b1\u200927.0\u2009h after vaccination and last an average duration of 14.2\u2009\u00b1\u200921.3\u2009h. Only 9.7% of those affected also report headaches resulting from previous vaccinations. In 66.6% of the participants, headache occurs as a single episode. A bilateral location is indicated by 73.1% of the participants. This is most often found on the forehead (38.0%) and temples (32.1%). A pressing pain character is indicated by 49.2% and 40.7% report a dull pain character. The pain intensity is most often moderate (46.2%), severe (32.1%) or very severe (8.2%). The most common accompanying symptoms are fatigue (38.8%), exhaustion (25.7%) and muscle pain (23.4%). Headaches after COVID-19 vaccination show an extensive complex of symptoms. The constellation of accompanying symptoms together with the temporal and spatial headache characteristics delimit a distinctive headache phenotype.<\/jats:p>","DOI":"10.1093\/braincomms\/fcab169","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T11:10:14Z","timestamp":1626952214000},"source":"Crossref","is-referenced-by-count":65,"title":["Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-6936","authenticated-orcid":false,"given":"Carl H","family":"G\u00f6bel","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"},{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Karstedt","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"},{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Morscheck","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cirkel","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"},{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutayba","family":"Hamid","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Hani","family":"Temsah","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Ziemann","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"G\u00f6rg","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcnte","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"2","key":"2022020823021365200_fcab169-B1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7150\/ijms.50873","article-title":"Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period","volume":"18","author":"Liu","year":"2021","journal-title":"Int J Med Sci"},{"key":"2022020823021365200_fcab169-B2","volume-title":"COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University","author":"Johns Hopkins University Coronavirus Resource Center"},{"issue":"3","key":"2022020823021365200_fcab169-B3","doi-asserted-by":"crossref","first-page":"e0241875","DOI":"10.1371\/journal.pone.0241875","article-title":"Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study","volume":"16","author":"Dixon","year":"2021","journal-title":"PLoS One"},{"key":"2022020823021365200_fcab169-B4","volume-title":"The COVID-19 candidate vaccine landscape","author":"World Health Organization"},{"issue":"27","key":"2022020823021365200_fcab169-B5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"2022020823021365200_fcab169-B6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - Preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"10267","key":"2022020823021365200_fcab169-B7","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2022020823021365200_fcab169-B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022020823021365200_fcab169-B9","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10275","key":"2022020823021365200_fcab169-B10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"2022020823021365200_fcab169-B11","author":"FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting"},{"issue":"1","key":"2022020823021365200_fcab169-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"10240","key":"2022020823021365200_fcab169-B13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10249","key":"2022020823021365200_fcab169-B14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2022020823021365200_fcab169-B15","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"issue":"10255","key":"2022020823021365200_fcab169-B16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"10249","key":"2022020823021365200_fcab169-B17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"2022020823021365200_fcab169-B18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"2022020823021365200_fcab169-B19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2022020823021365200_fcab169-B20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2022020823021365200_fcab169-B21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","article-title":"The migraine postdrome: An electronic diary study","volume":"87","author":"Giffin","year":"2016","journal-title":"Neurology"},{"issue":"13","key":"2022020823021365200_fcab169-B22","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1177\/0333102420965140","article-title":"Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study","volume":"40","author":"Magdy","year":"2020","journal-title":"Cephalalgia"},{"issue":"5","key":"2022020823021365200_fcab169-B23","first-page":"252","article-title":"SARS-CoV-2: Previous coronaviruses, immune response, and development of vaccines","volume":"77","author":"De Leon-Rodriguez","year":"2020","journal-title":"Bol Med Hosp Infant Mex"},{"issue":"6","key":"2022020823021365200_fcab169-B24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/15321819.2020.1865400","article-title":"Immunotherapies and COVID-19 related neurological manifestations: A comprehensive review article","volume":"41","author":"Anwar","year":"2020","journal-title":"J Immunoassay Immunochem"},{"issue":"11","key":"2022020823021365200_fcab169-B25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jsps.2020.08.024","article-title":"Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective","volume":"28","author":"Alnefaie","year":"2020","journal-title":"Saudi Pharm J"},{"key":"2022020823021365200_fcab169-B26","doi-asserted-by":"crossref","first-page":"628971","DOI":"10.3389\/fimmu.2020.628971","article-title":"Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses","volume":"11","author":"Schlickeiser","year":"2020","journal-title":"Front Immunol"},{"key":"2022020823021365200_fcab169-B27","doi-asserted-by":"crossref","first-page":"607918","DOI":"10.3389\/fimmu.2020.607918","article-title":"HCoV- and SARS-CoV-2 cross-reactive T cells in CVID patients","volume":"11","author":"Steiner","year":"2020","journal-title":"Front Immunol"},{"key":"2022020823021365200_fcab169-B28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7573\/dic.2020-5-1","article-title":"Neurological features of COVID-19 and their treatment: A review","volume":"9","author":"Orsucci","year":"2020","journal-title":"Drugs Context"},{"key":"2022020823021365200_fcab169-B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40122-021-00296-3","article-title":"Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study","author":"G\u00f6bel","year":"2021","journal-title":"Pain Ther"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcab169\/39484579\/fcab169.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/3\/3\/fcab169\/42381520\/fcab169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/3\/3\/fcab169\/42381520\/fcab169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T23:06:55Z","timestamp":1644361615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcab169\/6326794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcab169","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"fcab169"}}